首頁 > 市場調查報告書 > 製藥

精神疾病

市場調查報告書

商品編碼

2038397

產後憂鬱症治療市場商機、成長要素、產業趨勢分析及2026-2035年預測。

Postpartum Depression Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035

出版日期: 2026年04月17日 | 出版商:

Global Market Insights Inc. | 英文 141 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2025 年，全球產後憂鬱症(PPD) 治療市場價值將達到 10.5 億美元，並有望以 9.4% 的複合年成長率成長，到 2035 年達到 25.5 億美元。

隨著心理健康日益被視為產後護理的關鍵要素，該市場正在成長。新手媽媽產後憂鬱症率的上升顯著推動了對有效快速治療方法的需求。人們對精神疾病的認知不斷加深，以及醫療服務可近性的提高，使得更多女性能夠尋求醫療協助。治療方法的創新正在拓展治療選擇，並改善中重度病例的治療效果。醫療基礎設施的加強以及將心理健康服務納入產科護理體系，進一步促進了市場擴張。此外，提高公眾意識的宣傳活動和教育宣傳活動正在減少圍繞產後心理健康的污名化，從而實現早期診斷和介入。在持續的醫療進步、醫療服務可近性的改善以及對孕產婦健康日益成長的關注的推動下，整體市場前景仍然光明。

市場範圍
開始年份	2025
預測期	2026-2035
上市時的市場規模	10.5億美元
預測金額	25.5億美元
複合年成長率	9.4%

產後憂鬱症是一種影響女性分娩後的精神障礙，與情緒、心理和生理變化有關。如果處理不當，會嚴重影響母親照顧自己和嬰兒的能力。常見症狀包括持續悲傷、焦慮、疲倦、易怒、難以與新生兒建立親密關係、無助感。治療通常包括藥物介入、心理諮商和支持性護理，旨在穩定情緒和提升整體健康水平。人們對這種疾病的認知不斷提高，促使產科醫療保健系統更好地整合篩檢和治療。

預計到2025年，藥物治療市場規模將達到5.91億美元，到2035年將以9.3%的複合年成長率成長。這一市場成長主要受有效藥物治療需求增加和治療選擇日益普及的推動。選擇性血清素再回收抑制劑（SSRIs）和血清素-正腎上腺素再回收抑制劑（SNRIs）等藥物因其在治療憂鬱症和焦慮症相關症狀方面的顯著療效而被廣泛應用。這些治療方法的雙重治療作用促進了其應用，尤其是在合併焦慮症的情況下。藥物研發的進步和安全性的提高進一步推動了藥物治療在臨床實踐中的應用。

到2025年，醫院藥局將佔據47.3%的市場佔有率，這反映了其在提供專科治療方法發揮的關鍵作用。醫院藥局是取得需要醫療監督給藥的先進治療方法的主要網路基地台。與住院和門診醫療系統的協調配合，確保了治療的順利進行，並改善了患者的治療效果。醫院內訓練有素的醫護人員的存在，進一步支持了安全有效的藥物管理，凸顯了這個管道在整體治療中的重要性。

受產後憂鬱症高發病率和孕產婦心理健康意識不斷提高的推動，預計到2025年，北美產後憂鬱症治療市場規模將達到4.346億美元。完善的醫療衛生基礎設施、廣泛的篩檢工作以及心理健康服務取得管道的改善，使得早期診斷和治療成為可能。此外，成熟的醫療衛生體系和人們對孕產婦保健日益成長的關注，也進一步促進了該地區市場的擴張。

生態系分析
影響產業的因素
- 促進因素
  - 產後憂鬱症盛行率增加
  - 藥物研發進展
  - 人們對女性健康的認知和關注度不斷提高
- 產業潛在風險與挑戰
  - 因相關副作用引起的安全性問題
  - 產後憂鬱症藥物高成本
- 市場機遇
  - 數位治療方案的擴展
  - 一種新型快速治療方法。
成長潛力分析
監理情勢（基於初步調查）
- 北美洲
  - 美國
  - 加拿大
- 歐洲
- 亞太地區
- 拉丁美洲
- 中東和非洲
管道分析
價格分析（基於初步調查）
未來市場趨勢（基於初步研究）
人工智慧和生成式人工智慧對市場的影響（基於初步研究）
波特五力分析
PESTEL 分析

第4章競爭情勢

介紹
企業市佔率分析
- 北美洲
- 歐洲
- 亞太地區
企業矩陣分析
主要市場公司的競爭分析
競爭定位矩陣
主要進展
- 併購
- 夥伴關係與合作
- 新產品發布
- 業務拓展計劃

第5章市場估計與預測：依類型分類，2022-2035年

產後焦慮
產後憂鬱
產後創傷後壓力症候群（PTSD）
產後強迫症（OCD）
產後驚恐障礙
產後精神病

第6章市場估計與預測：依治療方法，2022-2035年

藥物治療
- 選擇性血清素再回收抑制劑（SSRIs）
- 正腎上腺素再回收抑制劑（SNRIs）
- 三環抗憂鬱藥物（TCAs）
- 其他藥物療法
荷爾蒙療法
其他治療方法

第7章市場估計與預測：依給藥途徑分類，2022-2035年

口服
腸外
其他給藥途徑

第8章市場估算與預測：依通路分類，2022-2035年

醫院藥房
零售藥房
網路藥房

第9章市場估計與預測：依地區分類，2022-2035年

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 荷蘭
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國

第10章：公司簡介

AstraZeneca
博士倫健康公司
Cipla
Eli Lilly and Company
GlaxoSmithKline
Merck
Novartis
Pfizer
Sun Pharmaceutical Industries
Supernus Pharmaceuticals
Takeda Pharmaceutical
Teva Pharmaceutical Industries

簡介目錄

Product Code: 13090

The Global Postpartum Depression (PPD) Treatment Market was valued at USD 1.05 billion in 2025 and is estimated to grow at a CAGR of 9.4% to reach USD 2.55 billion by 2035.

Postpartum Depression Treatment Market - IMG1

The market is experiencing growth due to rising recognition of mental health as a critical component of maternal care. Increasing incidence of postpartum depression among new mothers is significantly driving demand for effective and timely treatment options. Growing acceptance of mental health disorders and improved access to healthcare services are encouraging more women to seek medical support. Advances in therapeutic innovation have expanded treatment possibilities, improving outcomes for moderate to severe cases. Strengthening healthcare infrastructure and enhanced integration of mental health services into maternal care systems are further supporting market expansion. Public awareness initiatives and education campaigns are also reducing stigma associated with postpartum mental health conditions, enabling earlier diagnosis and intervention. The overall market outlook remains positive, supported by continuous medical advancements, improved accessibility, and increasing focus on maternal well-being.

Market Scope
Start Year	2025
Forecast Year	2026-2035
Start Value	$1.05 Billion
Forecast Value	$2.55 Billion
CAGR	9.4%

Postpartum depression is a mental health condition that affects women following childbirth and is associated with emotional, psychological, and physical changes. It can significantly impact a mother's ability to care for herself and her infant if not properly managed. Common symptoms include persistent sadness, anxiety, fatigue, irritability, difficulty in bonding with the newborn, and feelings of inadequacy. Treatment typically involves medical intervention, counseling, and supportive care aimed at improving emotional stability and overall well-being. Increasing recognition of the condition has led to greater integration of screening and treatment within maternal healthcare systems.

The pharmacotherapy segment generated USD 591 million in 2025 and is expected to grow at a CAGR of 9.3% over 2035. Growth in this segment is supported by rising demand for effective pharmaceutical interventions and improved accessibility to treatment options. Medications such as selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors are widely used due to their proven efficacy in managing depressive and anxiety-related symptoms. The dual therapeutic benefits of these treatments have contributed to their increasing adoption, particularly in cases where co-occurring anxiety is present. Advancements in drug development and improved safety profiles are further strengthening the use of pharmacological therapies in clinical practice.

The hospital pharmacies segment accounted for 47.3% share in 2025, reflecting its strong role in the distribution of specialized treatment options. Hospital-based pharmacies serve as key access points for advanced therapies that require medical supervision during administration. Their integration with inpatient and outpatient care systems ensures coordinated treatment delivery and improved patient outcomes. The presence of trained healthcare professionals within hospital settings further supports safe and effective medication management, reinforcing the importance of this channel in the overall treatment landscape.

North America Postpartum Depression Treatment Market was valued at USD 434.6 million in 2025 supported by a high prevalence of postpartum depression and increasing awareness regarding maternal mental health. Strong healthcare infrastructure, widespread screening initiatives, and improved access to mental health services are enabling early diagnosis and treatment. The presence of well-established healthcare systems and growing emphasis on maternal care are further contributing to regional market expansion.

Key companies operating in the Global Postpartum Depression Treatment Market include Eli Lilly and Company, Pfizer, Novartis, AstraZeneca, GlaxoSmithKline, Takeda Pharmaceutical, Teva Pharmaceutical Industries, Sun Pharmaceutical Industries, Cipla, Merck, Supernus Pharmaceuticals, and Bausch Health Companies. Companies in the Postpartum Depression Treatment Market are focusing on innovation, clinical research, and strategic collaborations to strengthen their market position. Continuous investment in drug development is enabling the introduction of more effective and safer therapeutic options. Market players are expanding their clinical trial activities to improve treatment efficacy and address unmet medical needs. Strengthening partnerships with healthcare providers is enhancing awareness and adoption of treatment solutions. Companies are also working on improving accessibility through expanded distribution networks and healthcare partnerships. Emphasis on regulatory approvals and patient-centric therapies is further supporting market growth.

Chapter 1 Methodology and Scope

1.1 Market scope and definition
1.2 Research approach
1.3 Quality commitments
- 1.3.1 GMI AI policy and data integrity commitment
  - 1.3.1.1 Source consistency protocol
1.4 Research trail and confidence scoring
- 1.4.1 Research trail components
- 1.4.2 Scoring components
1.5 Data collection
- 1.5.1 Partial list of primary sources
1.6 Data mining sources
- 1.6.1 Paid sources
  - 1.6.1.1 Sources, by region
1.7 Base estimates and calculations
- 1.7.1 Revenue share analysis
- 1.7.2 Base year calculation
1.8 Forecast model
1.9 Research transparency addendum
- 1.9.1 Source attribution framework
- 1.9.2 Quality assurance metrics
- 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

2.1 Industry 360° synopsis
2.2 Key market trends
- 2.2.1 Business trends
- 2.2.2 Regional trends
- 2.2.3 Type trends
- 2.2.4 Treatment trends
- 2.2.5 Route of administration trends
- 2.2.6 Distribution channel trends
2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of postpartum depression
  - 3.2.1.2 Advancements in drug development
  - 3.2.1.3 Growing awareness and focus on women's health
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Safety concerns due to associated side effects
  - 3.2.2.2 High cost of postpartum depression drugs
- 3.2.3 Market opportunities
  - 3.2.3.1 Expansion of digital therapeutic solutions
  - 3.2.3.2 Emergence of fast-acting and novel therapies
3.3 Growth potential analysis
3.4 Regulatory landscape (Driven by primary research)
- 3.4.1 North America
  - 3.4.1.1 U.S.
  - 3.4.1.2 Canada
- 3.4.2 Europe
- 3.4.3 Asia Pacific
- 3.4.4 Latin America
- 3.4.5 Middle East and Africa
3.5 Pipeline analysis
3.6 Pricing analysis (Driven by primary research)
3.7 Future market trends (Driven by primary research)
3.8 Impact of AI and Generative AI on the market (Driven by primary research)
3.9 Porter's analysis
3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

4.1 Introduction
4.2 Company market share analysis
- 4.2.1 North America
- 4.2.2 Europe
- 4.2.3 Asia Pacific
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Key developments
- 4.6.1 Merger and acquisition
- 4.6.2 Partnership and collaboration
- 4.6.3 New product launches
- 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Type, 2022 - 2035 ($ Mn)

5.1 Key trends
5.2 Postpartum anxiety
5.3 Postpartum blues
5.4 Postpartum post-traumatic stress disorder (PTSD)
5.5 Postpartum obsessive-compulsive disorder (OCD)
5.6 Postpartum panic disorder
5.7 Postpartum psychosis

Chapter 6 Market Estimates and Forecast, By Treatment, 2022 - 2035 ($ Mn)

6.1 Key trends
6.2 Pharmacotherapy
- 6.2.1 Selective serotonin reuptake inhibitors (SSRIs)
- 6.2.2 Serotonin norepinephrine reuptake inhibitors (SNRIs)
- 6.2.3 Tricyclic antidepressants (TCA)
- 6.2.4 Other pharmacotherapies
6.3 Hormone therapy
6.4 Other treatments

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Parenteral
7.4 Other routes of administration

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Italy
- 9.3.5 Spain
- 9.3.6 Netherlands
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE